Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07522099 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chinese Adults With Kidney Disease

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 9 sitesv9
  2. Study sites: 10 to 9v8
  3. Site details revised at 1 of 10 sitesv7
  4. Re-verified, no change to tracked fieldsv6
  5. Start date changed from estimate of Jul 23, 2026 to May 21, 2026 Site details revised at 1 of 10 sitesv5 Show 1 more changeShow less
    • Site details revised at 1 of 10 sites
  6. Site details revised at 1 of 10 sitesv4
  7. Trial sites expanded: 5 → 10 locationsv3
  8. Recruitment opened Trial sites expanded: 0 → 5 locations · Completion pushed from Jul 10, 2028 to Jan 21, 2029v2 Show 2 more changesShow less
    • Trial sites expanded: 0 → 5 locations
    • Completion pushed from Jul 10, 2028 to Jan 21, 2029
  9. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
Trial Details
NCT Number NCT07522099
Lead Sponsor ADARx Pharmaceuticals, Inc.
Conditions Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov